The complaint alleges that Ardelyx provided positive outlooks while concealing material difficulties surrounding its drugs, XPHOZAH and IBSRELA. Specifically, the lawsuit claims the company failed to disclose growing reimbursement and payer-related barriers, including stringent prior authorization and step edit requirements. These obstacles reportedly slowed new-patient starts and hindered prescription fulfillment, causing financial losses for investors once the true state of the company's growth prospects reached the market.

Rosen Law Firm, which represents investors in the action, is currently soliciting participants to join the case. While a lawsuit has been filed, no class has been certified yet. Investors retain the option to hire their own counsel, remain absent class members, or seek to lead the litigation. Those choosing to participate can contact Phillip Kim at 866-767-3653 or through the firm's website. Participation in any future financial recovery is not contingent upon serving as lead plaintiff.